Nona-arginine

Summary

Nona‑arginine (R9, also called Poly‑arginine‑9) is a nine‑amino‑acid, positively charged cell‑penetrating peptide employed in research as a non‑viral carrier for proteins, DNA, RNA and other macromolecules. Its cationic nature enables rapid entry into many cell types, and it has been explored for topical skin delivery, intravenous administration, and intracellular vectoring, but it has no approved therapeutic use.

Mechanism of Action

R9 consists of nine consecutive arginine residues that confer a high positive charge. The peptide electrostatically binds to negatively charged cell‑surface glycosaminoglycans, triggering uptake primarily through endocytic pathways such as macropinocytosis. When complexed with nucleic acids, the peptide forms condensed particles that protect the cargo and facilitate cellular entry. Release from endosomes often requires additional endosomolytic agents or peptide modifications, because sequestration in vesicles can limit delivery to the cytoplasm or nucleus.

What the Research Shows

Early work demonstrated that a fluorescently labelled R9 conjugate can penetrate human skin after topical application, with time‑dependent diffusion through the extracellular matrix (Chem Commun 2015). A 2011 review highlighted R9 as one of the most efficiently transported protein‑transduction domains, noting minimal cytotoxicity in vitro and potential for skin‑cancer immunotherapy. In vitro studies with HeLa cells showed that R9 forms stable complexes with anti‑E6 shRNA, achieving high transfection efficiency at N/P ratios above 30 and resulting in significant knock‑down of HPV‑E6 mRNA and selective toxicity toward cancer cells (Iran Biomed J 2023). A broader overview of CPP‑mediated oligonucleotide delivery (Biochem Soc Trans 2007) described endocytic uptake as the dominant route and emphasized the need for endosomolytic strategies to improve nuclear delivery. Finally, an analytical study (ACS Omega 2025) developed a high‑resolution HPLC method to separate R9‑DNA conjugates, facilitating quality control of peptide‑oligonucleotide therapeutics.

Reported Benefits

R9 provides rapid, broad‑spectrum cellular uptake with low baseline cytotoxicity, enabling delivery of diverse cargos without viral vectors. Its strong electrostatic interaction with nucleic acids allows formation of compact complexes that protect RNA or DNA from degradation. In skin models, topical R9 penetrates the epidermis, suggesting utility for localized therapies. In vitro gene‑silencing experiments have demonstrated effective knock‑down of oncogenic transcripts, indicating potential for targeted molecular interventions.

Limitations of the Evidence

Most data are limited to in vitro or early‑stage animal models; there are few in vivo pharmacokinetic or efficacy studies. Endosomal entrapment reduces cytoplasmic release unless additional agents are used, and high N/P ratios can cause selective toxicity. The peptide’s lack of specificity may lead to off‑target uptake, and no clinical trials have been reported, leaving efficacy and safety in humans uncharacterized.

Safety Considerations

Across the cited studies, R9 exhibited minimal cytotoxicity at low concentrations, but toxicity increased at higher peptide‑to‑cargo ratios (e.g., N/P >30) and in some formulations combined with polyethylenimine. Potential membrane perturbation and immune activation have not been fully evaluated in vivo. Until human data are available, caution is advised when extrapolating safety, especially for systemic administration.

How It Is Administered

R9 is employed as a soluble peptide or as part of a peptide‑cargo conjugate. Reported routes include topical application to skin, intravenous injection for systemic delivery, and direct intracellular use in cell‑culture transfection protocols. Formulations typically involve aqueous solutions where the peptide is mixed with the therapeutic cargo to form electrostatic complexes prior to administration.

Routes of Administration

Goals & Uses

• enhance intracellular deliveryDeliveryModerate
• Transdermal delivery enhancementDrug DeliveryLow
• Intracellular drug deliveryDrug DeliveryHigh
• Vaccine adjuvant / antigen deliveryImmunologyLow
• Imaging agent deliveryDiagnosticsModerate
• Gene therapy vector enhancementGene TherapyModerate

Contraindications

• In vivo systemic use without validated formulationSafetyHigh
• Known hypersensitivity to polyarginine peptidesAllergy/ImmunologyHigh

Adverse Effects

• Cytotoxicity at high concentrationsIn Vitro ToxicityCommon
• Endosomal entrapment / inefficient endosomal escapePharmacokinetic LimitationCommon
• Membrane disruptionCellular ToxicityUnknown
• Complement activation / immunogenicityImmunologicalUnknown

Drug Interactions

• Anionic polymers (e.g., polyglutamic acid, DNA)Moderate
• Heparin / heparan sulfate-based compoundsHigh

Population Constraints

• Pregnant or lactating individualsReproductiveRelative
• Pediatric populationsAgeRelative
• Immunocompromised individualsImmunologicalRelative

Regulatory Status

• European UnionUnapprovedResearch use only.
• United StatesUnapprovedInvestigational reagent only.
• United KingdomUnapprovedNot approved by MHRA; research use only.

Not approved for therapeutic use; employed solely as a research reagent.

Evidence & Sources

• An easy-to-detect nona-arginine peptide for epidermal targeting
  Journal ArticleLowClède S, et al.2015-01-01T00:00:00.000000Z
• Novel immunotherapeutic approaches to skin cancer treatments using protein transduction technology
  Journal ArticleModerateShibagaki N, et al.2011-01-01T00:00:00.000000Z
• Nona-Arginine Mediated Anti-E6 ShRNA Delivery Suppresses the Growth of Hela Cells in vitro
  Journal ArticleLowTaghizadeh Pirposhteh R, et al.2023-01-01T00:00:00.000000Z
• Cell-penetrating-peptide-based delivery of oligonucleotides: an overview
  Journal ArticleModerateAbes R, et al.2007-01-01T00:00:00.000000Z
• Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides
  Journal ArticleModerateFeldman P, Khanna R2013-01-01T00:00:00.000000Z
• High-Resolution HPLC for Separating Peptide-Oligonucleotide Conjugates
  Journal ArticleLowNaganuma M, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions